- Home
- BBW vs TNGX Comparison
BBW vs TNGX Comparison
Compare BBW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBW
- TNGX
- Stock Information
- Founded
- BBW 1997
- TNGX 2014
- Country
- BBW United States
- TNGX United States
- Employees
- BBW N/A
- TNGX N/A
- Industry
- BBW Recreational Games/Products/Toys
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BBW Consumer Discretionary
- TNGX Health Care
- Exchange
- BBW Nasdaq
- TNGX Nasdaq
- Market Cap
- BBW 672.6M
- TNGX 723.2M
- IPO Year
- BBW 2004
- TNGX N/A
- Fundamental
- Price
- BBW $56.57
- TNGX $6.90
- Analyst Decision
- BBW Strong Buy
- TNGX Strong Buy
- Analyst Count
- BBW 5
- TNGX 6
- Target Price
- BBW $57.60
- TNGX $10.00
- AVG Volume (30 Days)
- BBW 231.3K
- TNGX 1.9M
- Earning Date
- BBW 08-28-2025
- TNGX 08-05-2025
- Dividend Yield
- BBW 1.55%
- TNGX N/A
- EPS Growth
- BBW 19.03
- TNGX N/A
- EPS
- BBW 4.15
- TNGX N/A
- Revenue
- BBW $510,069,000.00
- TNGX $24,296,000.00
- Revenue This Year
- BBW $6.10
- TNGX N/A
- Revenue Next Year
- BBW $3.90
- TNGX N/A
- P/E Ratio
- BBW $13.63
- TNGX N/A
- Revenue Growth
- BBW 6.09
- TNGX N/A
- 52 Week Low
- BBW $27.44
- TNGX $1.03
- 52 Week High
- BBW $59.78
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- BBW 59.90
- TNGX 56.63
- Support Level
- BBW $52.54
- TNGX $6.60
- Resistance Level
- BBW $59.78
- TNGX $7.42
- Average True Range (ATR)
- BBW 2.44
- TNGX 0.47
- MACD
- BBW 0.26
- TNGX -0.04
- Stochastic Oscillator
- BBW 69.49
- TNGX 57.20
About BBW Build-A-Bear Workshop Inc.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.